Developing A True Strategic Partnership


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

Product Description

The biopharmaceutical industry is facing intense pressure within research and development to bring new drugs to the market at a time when drug development has become complex and expensive. Blockbuster patent expirations, more complex protocols, increasing R&D costs, patient recruitment issues, and more stringent regulatory and safety issues are all challenging drug developers.
As a result, pharmaceutical and biotech companies are beginning to rethink their approach to outsourcing and how best to build alliances with external service providers, according to a panel of industry leaders recently convened…

Tips for Creating Strategic ­Partnerships
Sound bites From the Field

Edward J. Brennan, M.D., is President and CEO, IndiPharm Inc., a clinical research organization (CRO) providing the full range of clinical trial services. For more information, visit
Graham Bunn is VP, Partnerships and Alliances, Medidata Solutions, a global provider of SaaS-based clinical development solutions. For more information, visit
Kristan Gallitano is VP of Data Management Solutions at eClinical
Solutions, a division of Eliassen Group, and a clinical data management consulting firm. For more information, visit
Randy Kehrmeyer is President of Kforce Clinical Research, a professional staffing and solutions firm. For more information, visit
JF Marier, Ph.D., is VP and Lead Scientist, at Pharsight, a Certara company, a provider of software products and
scientific consulting services to facilitate improved productivity and strategic decision making in drug development. For more information, visit
Michael Soenen is President and CEO, ClearTrial, a provider of clinical trial operations (CTO) software. For more
information, visit
Rising Trial Complexity Continues to Vex Drug Developers

Vince Aurentz. Head of Customer ­Solutions, Quintiles, a services company ­offering clinical, commercial, consulting, and capital solutions worldwide. For more information, visit
Tim Dietlin. VP of Alliance Development, INC Research, a therapeutically focused contract research organization. For more information, visit
Mark A. Goldberg, M.D. Chief Operating Officer, Parexel International, a global services organization that provides the right level of guidance to bring safe and effective treatments to patients sooner. For more information, visit
Raymond Panas. Director of ­International Clinical Development, ­Sucampo Pharmaceuticals, which is focused on the development of medicines based on prostones. For more information, visit
Julian Remnant. R&D Advisory Lead Partner (Europe), Consulting, Deloitte, which offers professional services that cut across all ­segments of the healthcare and life-sciences industry. For more information, visit
Mark Roseman. Senior VP, Sales and Chief ­Marketing Officer, Kendle, a global clinical research ­organization providing a full range of early- to ­late-stage clinical development services. For more ­information, visit
Aize Smink. Executive VP, Global Clinical Development, Chiltern, a global contract research organization with experience
conducting Phase I to Phase IV ­clinical trials. For more information, visit
Colin Terry. Executive VP, Commercial Operations, Aptuit, an integrated services ­company that provides drug development and drug discovery solutions. For more information, visit ­
Gene Wright. Senior VP, Clinical Development, Zalicus Inc., a company that ­discovers and develops novel treatments for pain and immuno-inflammatory ­diseases. For more information, visit